Bone And Joint Health Supplements - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Bone And Joint Health Supplements Market Analysis

The bone and joint health supplements market generated USD 13.26 billion in 2025 and is forecast to advance at a 6.49% CAGR, reaching USD 18.16 billion by 2030. Growth in market size is driven by the rising prevalence of osteoporosis, a shift toward preventive self-care, and innovations in convenient supplementation formats. The aging population, at higher fracture risk, increasingly incorporates supplements like calcium, vitamin D, and joint-support formulations. Companies are adopting plant-based and marine-sourced ingredients to address sustainability and dietary preferences. Online retail platforms are reshaping the market by enhancing product discovery, price transparency, and global reach for niche brands. While regulatory frameworks support structure/function claims, stricter rules on novel ingredients are pushing larger companies to invest in compliance expertise.

Global Bone And Joint Health Supplements Market Trends and Insights

Rising global incidence of osteoporosis and joint-related disorders

The rising prevalence underscores a critical and growing demand for effective osteoporosis-related healthcare solutions, which now transcend traditional demographic boundaries. In 2023, the Italian National Institute of Statistics reported that 4,477 thousand individuals in Italy were affected by osteoporosis . The data highlights that the economic burden of untreated bone loss significantly exceeds the costs associated with routine supplementation and preventive care. As a result, healthcare professionals are increasingly advocating for the early adoption of targeted nutritional and therapeutic products. This proactive approach is broadening the addressable consumer base, encompassing not only the elderly population, who are traditionally at higher risk but also younger individuals who can benefit from preventive interventions aimed at mitigating long-term health risks.

Aging population with increased focus on mobility and bone strength

Demographic shifts are transforming demand patterns, extending beyond basic metrics of population aging. As of January 2024, the European Union reported a population of 449.3 million, with over one-fifth (21.6%) aged 65 and older . This demographic trend has led to an increase in disability-adjusted life years, particularly linked to musculoskeletal conditions. Rising life expectancy has heightened the demand for prolonged joint functionality. Consequently, there is growing interest in daily essentials such as collagen peptides, glucosamine, and vitamin K2, which are now viewed as integral to daily health rather than occasional remedies. The combination of an aging population and the increasing prevalence of related disorders is driving market demand, surpassing simple demographic projections. Older adults are becoming more proactive in maintaining mobility and independence. A notable trend of “healthy aging” has emerged, where older consumers prioritize preventive measures by investing in supplements rather than waiting for symptoms to manifest.

Regulatory challenges for health claims restrict growth

Structure/function claims are exempt from pre-market approval; however, every product label must include a disclaimer stating that the claim has not been reviewed by the FDA. This requirement can diminish consumer confidence in the product. Furthermore, the proposed removal of self-affirmed GRAS (Generally Recognized as Safe) status would necessitate companies to formally notify regulatory authorities about the inclusion of novel food ingredients. This change would result in extended product launch timelines and increased documentation-related expenses. Smaller companies, in particular, face significant challenges in complying with the differing regulatory frameworks of the United States, European Union, and China. These complexities disproportionately burden smaller firms and hinder innovation within the category.

Other drivers and restraints analyzed in the detailed report include:

1. Growing awareness of preventive healthcare and bone density management
2. Shift toward natural and plant-based bone health ingredients
3. High price of quality formulations deterring budget-conscious consumers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2024, vitamins and minerals accounted for 31.21% of total revenue, driven by strong endorsements from physicians for calcium-vitamin D regimens. Heightened awareness of vitamin D deficiency and its repercussions on bone health has spurred the demand for vitamin D supplements. Meanwhile, glucosamine-chondroitin is set to witness an 8.72% CAGR growth rate through 2030, fueled by findings that combination formulas with curcumin significantly alleviate pain more than glucosamine-chondroitin alone.

As a result, the glucosamine-chondroitin segment within the bone and joint health supplements market is expanding at a faster pace than any other ingredient category. This rapid growth has attracted notable investments, such as Zeria USA’s introduction of pharmaceutical-grade sodium chondroitin. Additionally, collagen, which was traditionally marketed for its beauty-enhancing properties, is now transitioning towards being positioned as a functional ingredient for joint health, with marine-sourced variants gaining particular traction in this evolving market segment.

The Bone and Joint Health Supplements Market Report is Segmented by Type (Vitamins and Minerals, Collagen, and More), Form (Tablets, Capsules/Softgels, Gummies and Chews, Powders, and Others), Distribution Channel (Supermarkets/Hypermarkets, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

In 2024, North America contributed 32.17% of global revenue, driven by established physician recommendations for calcium and vitamin D supplementation and a robust reimbursement framework. The FDA's 2024 approval of YORVIPATH (palopegteriparatide) highlights the seamless progression from supplements to advanced biologics, emphasizing the role of regulatory clarity in fostering innovation. E-commerce continues to grow steadily as consumers increasingly incorporate supplements into routine household purchases.

Asia-Pacific, anticipated to grow at an 8.23% CAGR, demonstrates significant untapped potential. China alone accounts for 145.86 million osteoporotic adults, as per WHO standards, while regulators are working on provisions to permit joint-health claims on health food labels. Haleon's decision to increase its stake in Tianjin TSKF Pharmaceutical to 88% reflects a long-term strategic commitment. Additionally, brand extensions such as Caltrate for expectant mothers in the Philippines illustrate a focus on micro-segmentation. Factors such as rapid urbanization, rising disposable incomes, and the expansion of mobile commerce are driving the adoption of bone and joint health supplements, positioning the region for sustained growth.

Europe maintains stable mid-single-digit growth, supported by innovations in plant-based products. Marine collagen and algal calcium are gaining popularity among sustainability-conscious consumers. Regulatory harmonization under EFSA facilitates multi-country product launches but imposes stringent evidence requirements, favoring well-funded companies. The Middle East, Africa, and South America remain in the early stages of market development. However, increasing rates of obesity and diabetes are raising awareness of joint health, signaling potential opportunities as distribution infrastructure continues to improve.

List of Companies Covered in this Report:

1. Amway Corporation
2. Swanson Health Products, Inc.
3. Nestle S.A.
4. Haleon plc
5. 21st Century HealthCare, Inc.
6. Bluebonnet Nutrition Corporation
7. Reckitt Benckiser Group plc
8. Herbalife Nutrition Ltd.
9. Otsuka Holdings Co., Ltd.
10. Nordic Naturals
11. NOW Foods
12. Harbin Pharmaceutical Group Co., Ltd.
13. Nutramax Laboratories Inc.
14. Dr. Willmar Schwabe GmbH & Co. KG
15. Life Extension Foundation Buyers Club, Inc.
16. Xtend-Life Group Ltd.
17. Codeage LLC
18. Xiamen Kingdomway Group Company
19. Vytalogy Wellness, L.L.C.
20. BioGaia AB

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support